Proactive Investors - Run By Investors For Investors

Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019

Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

Vyome Therapeutics is a clinical stage speciality pharmaceutical company, with platform technologies and a pipeline of drugs for antibiotic-resistant acne and other skin pathogens.

 
View full VYOME profile View Profile

Vyome Therapeutics Inc. Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use